Latest Biologic Stories
Treatment for lifelong skin disease that affects nearly a million Canadians showed significant and clinically meaningful improvements in clinical studies Canadian approval comes
Study finds that the Solstice-licensed technology allows efficient delivery of RNAi prodrugs SAN DIEGO, Nov.
EDISON, N.J., Nov.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
~Data to be presented at the American College of Rheumatology Annual Meeting CHARLOTTESVILLE, Va., Nov.
Company's collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug TORONTO and MONTREAL, Nov.
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
DALLAS, November 3, 2014 /PRNewswire/ -- According to the new market research report The "Single Use Bioreactor Market by Product Type (Recombinant Proteins, Monoclonal
- The word or words serving to define another word or expression, as in a dictionary entry.